Advanced search
1 file | 1.54 MB

Is there new hope for therapeutic matrix metalloproteinase inhibition?

(2014) NATURE REVIEWS DRUG DISCOVERY. 13(12). p.904-927
Author
Organization
Abstract
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that form a family of 24 members in mammals. Evidence of the pathological roles of MMPs in various diseases, combined with their druggability, has made them attractive therapeutic targets. Initial drug discovery efforts focused on the roles of MMPs in cancer progression, and more than 50 MMP inhibitors have been investigated in clinical trials in various cancers. However, all of these trials failed. Reasons for failure include the lack of inhibitor specificity and insufficient knowledge about the complexity of the disease biology. MMPs are also known to be involved in several inflammatory processes, and there are new therapeutic opportunities for MMP inhibitors to treat such diseases. In this Review, we discuss the recent advances made in understanding the role of MMPs in inflammatory diseases and the therapeutic potential of MMP inhibition in those conditions.
Keywords
EXACERBATES EXPERIMENTAL COLITIS, SELECTIVE MMP-13 INHIBITORS, COMPLICATED DIVERTICULAR-DISEASE, CHEMICALLY-MODIFIED TETRACYCLINES, GELATINASE B/MATRIX METALLOPROTEINASE-9, GENE KNOCK-OUT, NECROSIS-FACTOR-ALPHA, BLOOD-BRAIN-BARRIER, FOCAL CEREBRAL-ISCHEMIA, INFLAMMATORY-BOWEL-DISEASE

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.54 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Vandenbroucke, Roosmarijn, and Claude Libert. 2014. “Is There New Hope for Therapeutic Matrix Metalloproteinase Inhibition?” Nature Reviews Drug Discovery 13 (12): 904–927.
APA
Vandenbroucke, Roosmarijn, & Libert, C. (2014). Is there new hope for therapeutic matrix metalloproteinase inhibition? NATURE REVIEWS DRUG DISCOVERY, 13(12), 904–927.
Vancouver
1.
Vandenbroucke R, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? NATURE REVIEWS DRUG DISCOVERY. 2014;13(12):904–27.
MLA
Vandenbroucke, Roosmarijn, and Claude Libert. “Is There New Hope for Therapeutic Matrix Metalloproteinase Inhibition?” NATURE REVIEWS DRUG DISCOVERY 13.12 (2014): 904–927. Print.
@article{5769425,
  abstract     = {Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that form a family of 24 members in mammals. Evidence of the pathological roles of MMPs in various diseases, combined with their druggability, has made them attractive therapeutic targets. Initial drug discovery efforts focused on the roles of MMPs in cancer progression, and more than 50 MMP inhibitors have been investigated in clinical trials in various cancers. However, all of these trials failed. Reasons for failure include the lack of inhibitor specificity and insufficient knowledge about the complexity of the disease biology. MMPs are also known to be involved in several inflammatory processes, and there are new therapeutic opportunities for MMP inhibitors to treat such diseases. In this Review, we discuss the recent advances made in understanding the role of MMPs in inflammatory diseases and the therapeutic potential of MMP inhibition in those conditions.},
  author       = {Vandenbroucke, Roosmarijn and Libert, Claude},
  issn         = {1474-1776},
  journal      = {NATURE REVIEWS DRUG DISCOVERY},
  language     = {eng},
  number       = {12},
  pages        = {904--927},
  title        = {Is there new hope for therapeutic matrix metalloproteinase inhibition?},
  url          = {http://dx.doi.org/10.1038/nrd4390},
  volume       = {13},
  year         = {2014},
}

Altmetric
View in Altmetric
Web of Science
Times cited: